Marlan D. Walker - May 10, 2021 Form 4 Insider Report for TherapeuticsMD, Inc. (TXMD)

Signature
/s/ Marlan D. Walker
Stock symbol
TXMD
Transactions as of
May 10, 2021
Transactions value $
-$22,456
Form type
4
Date filed
5/12/2021, 08:43 PM
Next filing
Jul 2, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXMD Common Stock Options Exercise +50.5K 50.5K May 10, 2021 Direct F1
transaction TXMD Common Stock Sale -$22.5K -21.6K -42.76% $1.04 28.9K May 11, 2021 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXMD Restricted Stock Units Options Exercise $0 -50.5K -33.33% $0.00 101K May 10, 2021 Common Stock 50.5K $0.00 Direct F1, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 10, 2021, the reporting person received 50,500 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on March 30, 2021.
F2 The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.
F3 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $1.03 to $1.06 for an average weighted sale price of $1.04. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F4 Each RSU represents a contingent right to receive one share of issuer common stock upon settlement.
F5 The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023.